CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Four-Year Entecavir Treatment in Nucleoside-Naïve HBeAg(+) Patients: Results from Studies ETV-022 and -901
DOI 10.1055/s-0028-1089821
Bibliografische Angaben
Nachweis in CareLit
Autor:innenS Han, T Chang, YC Chao, SK Yoon, RG Gish, H Cheinquer, FJ Carrilho, H Zhang, H Brett-Smith, N Spiegelmacher, A Schwendel, T Pichl, I Reeb, R Hindes
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe09/2008
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: Entecavir (ETV) 0.5mg demonstrated superior virologic suppression compared to lamivudine (LVD) 100mg in study ETV-022. One hundred and eighty-three entecavir-treated patients from ETV-022 enrolled in rollover study ETV-901. We present efficacy and safety results in a cohort of patients from ETV studies -022 and -901 who received a total of 4 years of therapy with ETV. Methods: The nucleoside-naïve HBeAg(+) 4-y…
Zitieren
Zitierempfehlung
S Han, T Chang, YC Chao, SK Yoon, RG Gish, H Cheinquer, FJ Carrilho, H Zhang, H Brett-Smith, N Spiegelmacher, A Schwendel, T Pichl, I Reeb, R Hindes (2008) Four-Year Entecavir Treatment in Nucleoside-Naïve HBeAg(+) Patients: Results from Studies ETV-022 and -901. Zeitschrift für Gastroenterologie (09). https://doi.org/10.1055/s-0028-1089821
Mit CareLit weiterarbeiten